Articles related to GASTRIC ADENOCARCINOMA
A Deep Dive into the Management of AEs Associated with ADCs
HER2-Directed ADCs in Gastric Cancer Several antibody-drug conjugates (ADCs) have recently received approval for use in treating a range of solid cancers. This poses difficulties when handling a variety of adverse treatment-related events, some of which can take practitioners into uncharted area. After viewing this CME activity, medical oncologists, pulmonologists, urologists, pathologists, oncology NPs, PAs, oncology nurses, oncology pharmacists, and other HCPs caring for patients with solid tumors should be able to describe the elements of an antibody-drug conjugate (ADC) that may cause adverse events (AEs), identify AEs that result in treatment interruption or discontinuation, and suggest a strategy for managing the key AEs.
Oncology, Medical January 23rd 2023
Phase 2 trial in oeso-gastric adenocarcinoma (OSA) showed pathologic complete response in 59% of patients. Data update expected at ASCO 2022.
Neo-adjuvant therapy with nivolumab and ipilimumab is associated with a high pCR rate in ptsd with MSI/dMMR resectable OGA.
Oncology, Medical May 10th 2022